Home › Companies › KURA ONCOLOGY INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and KURA ONCOLOGY INC.’s Form 8-K, filed June 7, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 5, 2024: 5 items on KURA ONCOLOGY INC.’s Form 8-K, filed June 7, 2024: 3 approved · 2 passed (calculated).
Notable dissent: 2 directors (11.5%, 10.9% against); 1 other board item (18.3% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore KURA ONCOLOGY INC. in the interactive database Compare manager voting policies
These tallies are KURA ONCOLOGY INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 7, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Troy E. Wilson, Ph.D., J.D. | 59,332,182 | -- | -- | 7,740,382 | 2,690,089 | 88% | Passed (calculated) | — |
| Elect Director: Faheem Hasnain | 59,745,514 | -- | -- | 7,327,050 | 2,690,089 | 89% | Passed (calculated) | — |
| 2. Ratification of the Selection of Independent Registered Public Accounting Firm | 69,596,811 | 56,740 | 109,102 | -- | -- | 99.9% | Approved | — |
| 3. Advisory Vote on Executive Compensation | 61,538,693 | 5,449,767 | 111,285 | -- | 2,662,908 | 92% | Approved | — |
| 4. Approval of our Amended 2014 Plan | 53,621,818 | 11,993,394 | 1,484,533 | -- | 2,662,908 | 82% | Approved | — |
Source: KURA ONCOLOGY INC., Form 8-K, filed with the SEC on June 7, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
183 asset managers disclosed a vote on at least one KURA ONCOLOGY INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: Election of two Class I directors for three-year terms: Faheem Hasnain
KURA ONCOLOGY INC.’s own tally for this item (“Elect Director: Faheem Hasnain”): 59,745,514 for, 7,327,050 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 58 asset managers below reported 14,540,147 for, 1,928,217 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,968,562 | 0 | 0 | 0 | For |
| BlackRock | 3,144,096 | 0 | 0 | 0 | For |
| State Street | 2,554,088 | 0 | 0 | 37,562 | For |
| Fidelity | 1,706,693 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 996,915 | Withhold |
| FRANKLIN STRATEGIC SERIES | 967,982 | 0 | 0 | 0 | For |
| Charles Schwab | 599,027 | 0 | 0 | 0 | For |
| JPMorgan | 305,460 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 213,276 | Withhold |
| Invesco | 203,663 | 0 | 0 | 0 | For |
| Equitable | 107,966 | 0 | 0 | 83,100 | Mixed |
| TIAA | 175,690 | 0 | 0 | 0 | For |
| Russell Investments | 150,483 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 131,528 | 0 | 0 | 0 | For |
| Lincoln Financial | 82,663 | 0 | 0 | 38,615 | Mixed |
| American Century | 0 | 0 | 0 | 109,809 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 91,413 | Withhold |
| Exchange Place Advisors Trust | 84,620 | 0 | 0 | 0 | For |
| Northern Trust | 73,540 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 64,795 | Withhold |
| Voya | 56,077 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 0 | 53,700 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 45,624 | Withhold |
| Global X | 32,116 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 30,211 | 0 | 0 | 0 | For |
Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: Election of two Class I directors for three-year terms: Troy E. Wilson, Ph.D, J.D.
KURA ONCOLOGY INC.’s own tally for this item (“Elect Director: Troy E. Wilson, Ph.D., J.D.”): 59,332,182 for, 7,740,382 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 58 asset managers below reported 14,657,815 for, 1,810,549 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,968,562 | 0 | 0 | 0 | For |
| BlackRock | 3,144,096 | 0 | 0 | 0 | For |
| State Street | 2,554,088 | 0 | 0 | 37,562 | For |
| Fidelity | 1,706,693 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 996,915 | Withhold |
| FRANKLIN STRATEGIC SERIES | 967,982 | 0 | 0 | 0 | For |
| Charles Schwab | 599,027 | 0 | 0 | 0 | For |
| JPMorgan | 305,460 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 213,276 | Withhold |
| Invesco | 203,663 | 0 | 0 | 0 | For |
| Equitable | 191,066 | 0 | 0 | 0 | For |
| TIAA | 175,690 | 0 | 0 | 0 | For |
| Russell Investments | 150,483 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 131,528 | 0 | 0 | 0 | For |
| Lincoln Financial | 82,663 | 0 | 0 | 38,615 | Mixed |
| American Century | 0 | 0 | 0 | 109,809 | Withhold |
| Goldman Sachs | 91,413 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 84,620 | 0 | 0 | 0 | For |
| Northern Trust | 73,540 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 64,795 | Withhold |
| Voya | 0 | 0 | 0 | 56,077 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 53,700 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 45,624 | Withhold |
| Global X | 32,116 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 30,211 | 0 | 0 | 0 | For |
Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
82% Approved · of votes cast
Description as filed by funds: APPROVAL OF AN AMENDMENT TO OUR AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN.
KURA ONCOLOGY INC.’s own tally for this item (“4. Approval of our Amended 2014 Plan”): 53,621,818 for, 11,993,394 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(4) approved our Amended 2014 Plan as disclosed in the proxy statement”
Support: 82% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of KURA ONCOLOGY INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Stock Compensation Plan” (2 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).
The 60 asset managers below reported 11,960,362 for, 4,555,563 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,968,562 | 0 | 0 | 0 | For |
| BlackRock | 3,144,096 | 0 | 0 | 0 | For |
| State Street | 27,922 | 2,563,728 | 0 | 0 | Against |
| Fidelity | 1,641,779 | 64,914 | 0 | 0 | For |
| Dimensional | 0 | 996,915 | 0 | 0 | Against |
| FRANKLIN STRATEGIC SERIES | 967,982 | 0 | 0 | 0 | For |
| Charles Schwab | 599,027 | 0 | 0 | 0 | For |
| JPMorgan | 305,460 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 213,276 | 0 | 0 | Against |
| Invesco | 203,663 | 0 | 0 | 0 | For |
| Equitable | 191,066 | 0 | 0 | 0 | For |
| TIAA | 175,690 | 0 | 0 | 0 | For |
| Russell Investments | 150,483 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 131,528 | 0 | 0 | 0 | For |
| Lincoln Financial | 25,564 | 95,714 | 0 | 0 | Mixed |
| American Century | 0 | 109,809 | 0 | 0 | Against |
| Goldman Sachs | 0 | 91,413 | 0 | 0 | Against |
| Exchange Place Advisors Trust | 84,620 | 0 | 0 | 0 | For |
| Northern Trust | 73,540 | 0 | 0 | 0 | For |
| ProShares | 0 | 64,795 | 0 | 0 | Against |
| Voya | 0 | 56,077 | 0 | 0 | Against |
| ALPS ETF Trust | 0 | 53,700 | 0 | 0 | Against |
| ALGERT GLOBAL LLC | 47,561 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 45,624 | 0 | 0 | Against |
| Global X | 32,116 | 0 | 0 | 0 | For |
Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).
Combines 9 wordings of this item as funds reported it.
92% Approved · of votes cast
Prior year: 98.3% for (May 31, 2023 meeting) ▼ 6.5 pts
Description as filed by funds: APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS DURING THE YEAR ENDED DECEMBER 31, 2023.
KURA ONCOLOGY INC.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 61,538,693 for, 5,449,767 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(3) approved, on an advisory basis, the compensation paid to our named executive officers as disclosed in the proxy statement”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,968,562 | 0 | 0 | 0 | For |
| BlackRock | 3,144,096 | 0 | 0 | 0 | For |
| State Street | 2,591,650 | 0 | 0 | 0 | For |
| Fidelity | 1,706,693 | 0 | 0 | 0 | For |
| Dimensional | 0 | 996,915 | 0 | 0 | Against |
| FRANKLIN STRATEGIC SERIES | 0 | 967,982 | 0 | 0 | Against |
| Charles Schwab | 0 | 599,027 | 0 | 0 | Against |
| JPMorgan | 305,460 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 213,276 | 0 | 0 | 0 | For |
| Invesco | 203,663 | 0 | 0 | 0 | For |
| Equitable | 191,066 | 0 | 0 | 0 | For |
| TIAA | 175,690 | 0 | 0 | 0 | For |
| Russell Investments | 0 | 150,483 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 131,528 | 0 | 0 | 0 | For |
| Lincoln Financial | 113,592 | 7,686 | 0 | 0 | Mixed |
| American Century | 109,809 | 0 | 0 | 0 | For |
| Goldman Sachs | 91,413 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 0 | 84,620 | 0 | 0 | Against |
| Simplify Exchange Traded Funds | 0 | 0 | 0 | 80,000 | Withhold |
| Northern Trust | 73,540 | 0 | 0 | 0 | For |
| ProShares | 64,795 | 0 | 0 | 0 | For |
| Voya | 56,077 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 53,700 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 45,624 | 0 | 0 | 0 | For |
| Global X | 0 | 32,116 | 0 | 0 | Against |
Fund voting reports, all 59 managers: 13,539,462 for, 2,928,902 against, 80,000 withheld. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| New York Life | 19,000,000 | 0 | 0 | 0 | For |
| EcoR1 Capital, LLC | 5,806,871 | 0 | 0 | 0 | For |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,570,766 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,411,571 | 0 | 0 | 0 | For |
| BVF INC/IL | 4,876,293 | 0 | 0 | 0 | For |
| State Street | 3,985,203 | 0 | 0 | 0 | For |
| BlackRock | 2,739,482 | 9,112 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 2,544,742 | 0 | 0 | 0 | For |
| Paradigm Biocapital Advisors LP | 2,398,541 | 0 | 0 | 0 | For |
| Foresite Capital Management IV, LLC | 1,849,947 | 0 | 0 | 0 | For |
| ARMISTICE CAPITAL, LLC | 1,738,699 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,705,203 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 30,929 | 1,510,138 | 0 | 0 | Against |
| COMMODORE CAPITAL LP | 1,525,000 | 0 | 0 | 0 | For |
| TCG Crossover Management, LLC | 1,423,642 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 651,398 | 0 | 0 | Against |
| Charles Schwab | 0 | 599,027 | 0 | 0 | Against |
| Northern Trust | 580,277 | 733 | 0 | 0 | For |
| DAFNA Capital Management LLC | 412,663 | 0 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 381,412 | 0 | 0 | 0 | For |
| JPMorgan | 372,486 | 0 | 0 | 0 | For |
| Verition Fund Management LLC | 348,007 | 0 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 346,954 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 305,390 | 0 | 0 | 0 | For |
| Logos Global Management LP | 0 | 300,000 | 0 | 0 | Against |
No total is shown for the institutional-manager reports: their sum exceeds the total votes cast at the meeting. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 99.9% for (May 31, 2023 meeting) unchanged
Description as filed by funds: RATIFICATION OF THE SELECTION OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2024.
KURA ONCOLOGY INC.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 69,596,811 for, 56,740 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(2) ratified the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 58 asset managers below reported 16,463,928 for, 4,436 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,968,562 | 0 | 0 | 0 | For |
| BlackRock | 3,144,096 | 0 | 0 | 0 | For |
| State Street | 2,587,214 | 4,436 | 0 | 0 | For |
| Fidelity | 1,706,693 | 0 | 0 | 0 | For |
| Dimensional | 996,915 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 967,982 | 0 | 0 | 0 | For |
| Charles Schwab | 599,027 | 0 | 0 | 0 | For |
| JPMorgan | 305,460 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 213,276 | 0 | 0 | 0 | For |
| Invesco | 203,663 | 0 | 0 | 0 | For |
| Equitable | 191,066 | 0 | 0 | 0 | For |
| TIAA | 175,690 | 0 | 0 | 0 | For |
| Russell Investments | 150,483 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 131,528 | 0 | 0 | 0 | For |
| Lincoln Financial | 121,278 | 0 | 0 | 0 | For |
| American Century | 109,809 | 0 | 0 | 0 | For |
| Goldman Sachs | 91,413 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 84,620 | 0 | 0 | 0 | For |
| Northern Trust | 73,540 | 0 | 0 | 0 | For |
| ProShares | 64,795 | 0 | 0 | 0 | For |
| Voya | 56,077 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 53,700 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 45,624 | 0 | 0 | 0 | For |
| Global X | 32,116 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 30,211 | 0 | 0 | 0 | For |
Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 76,181,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 5.21% |
| 2 | BlackRock | 4.13% |
| 3 | State Street | 3.40% |
| 4 | Fidelity | 2.24% |
| 5 | Dimensional | 1.31% |
| 6 | FRANKLIN STRATEGIC SERIES | 1.27% |
| 7 | Charles Schwab | 0.79% |
| 8 | JPMorgan | 0.40% |
| 9 | Direxion Shares ETF Trust | 0.28% |
| 10 | Invesco | 0.27% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | New York Life | 24.94% |
| 2 | EcoR1 Capital, LLC | 7.62% |
| 3 | SUVRETTA CAPITAL MANAGEMENT, LLC | 7.31% |
| 4 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 7.10% |
| 5 | BVF INC/IL | 6.40% |
| 6 | State Street | 5.23% |
| 7 | BlackRock | 3.61% |
| 8 | Avoro Capital Advisors LLC | 3.34% |
| 9 | Paradigm Biocapital Advisors LP | 3.15% |
| 10 | Foresite Capital Management IV, LLC | 2.43% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 9,515,135 | 12.49% | Form 13F, quarter ended March 31, 2024 |
| EcoR1 Capital, LLC | 7,683,597 | 10.09% | Proxy statement (DEF 14A), proxy filed April 12, 2024 |
| Suvretta Capital Management, LLC | 7,670,468 | 10.07% | Proxy statement (DEF 14A), proxy filed April 12, 2024 |
| BVF Partners L.P. | 7,631,926 | 10.02% | Proxy statement (DEF 14A), proxy filed April 12, 2024 |
| S | 7,472,343 | 9.81% | Schedule 13G, filed February 13, 2024 |
| Deerfield Management Company, L.P. | 5,839,229 | 7.66% | Proxy statement (DEF 14A), proxy filed April 12, 2024 |
| Vanguard Group | 5,468,522 | 7.18% | Form 13F, quarter ended March 31, 2024 |
| State Street | 4,199,954 | 5.51% | Form 13F, quarter ended March 31, 2024 |
| Goldman Sachs | 2,614,726 | 3.43% | Form 13F, quarter ended March 31, 2024 |
| Troy E. Wilson, Ph.D., J.D. | 2,290,638 | 3.01% | Proxy statement (DEF 14A), proxy filed April 12, 2024 |
Percentages above are of 76,181,000 shares outstanding, as reported by KURA ONCOLOGY INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At KURA ONCOLOGY INC.'s shareholder meeting held June 5, 2024, in the 2023-2024 proxy season, 183 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,100 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS DURING THE… — KURA ONCOLOGY INC.'s filing reports the proposal as approved, with 92% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: KURA ONCOLOGY INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 7, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KURA ONCOLOGY INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
KURA ONCOLOGY INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “KURA ONCOLOGY (KURA) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/kura-oncology-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.